The North America Bio Decontamination Market should witness market growth of 6.1% CAGR during the forecast period (2023-2030).
The expanding pharmaceutical and biotechnology sectors propel the market for bio-decontamination, an increase in hospital-acquired illnesses, and a rise in the need for affordable and transportable solutions. Bio-decontamination products are frequently used by pharmaceutical and biotechnology firms, primarily for producing parenteral drugs. Thus, the necessity for production facilities outfitted with cutting-edge equipment, including UV-C disinfection robots and a decontaminated atmosphere, is crucial given the increased R&D spending and rising demand for novel pharmaceuticals and therapies. There will be a greater need for bio-decontamination goods to conduct effective research and manufacturing.
Another aspect fueling the market's revenue growth is improved bio-decontamination service outsourcing. Pharmaceutical production facilities and business laboratories must employ strict contamination control measures. Given that contamination control must be largely a preventative strategy, cleaning and disinfection procedures must be carried out with great care. Decontamination can be outsourced as a viable solution when there has been some intervention in the region (new installation, maintenance, etc.) or when it is only being done annually or biannually as a precautionary measure. This development in outsourcing services is anticipated to promote market revenue growth.
Chronic disease is one of the most common and expensive medical disorders in the US. Approximately 45% of all Americans, or 133 million people, have at least one chronic illness, which is steadily rising. Chronic conditions can lead to hospitalization, long-term impairment, a decline in quality of life, and even death. These conditions include stroke,cancer, diabetes, respiratory illnesses, hypertension, heart conditions, arthritis, obesity, and oral illnesses. The main cause of death and disability in the US is persistent conditions.
In Canada's Northwest Territories, chronic diseases are to blame for seven out of ten causes of death, with cancer or heart disease accounting for almost half of all fatalities. Furthermore, as the population ages, it is predicted that the burden of chronic disease will rise. Asthma, diabetes, chronic obstructive pulmonary disease,hypertension, and mental disorders are all common and rising in the Northwest Territories. There is expected to be an increase in the requirement for bio decontamination in medical facilities due to the increased incidence of chronic diseases, which also increases the frequency of admissions,hospital visits,and surgeries.
The US market dominated the North America Bio Decontamination Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $99,141.7 Thousands by 2030. The Canada market is showcasing a CAGR of 8.5% during (2023-2030). Additionally, The Mexico market would register a CAGR of 7.6% during (2023-2030).
Based on Agent Type, the market is segmented into Hydrogen Peroxide, Chlorine Dioxide, Paracetic Oxide, and Nitrogen Dioxide. Based on Product & Service, the market is segmented into Equipment, Services, and Consumables. Based on Type, the market is segmented into Chamber Decontamination, and Room Decontamination. Based on End-user, the market is segmented into Pharma & Medical Device Companies, Life Science & Biotechnology Research Organizations, and Hospitals & Healthcare Facilities. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include STERIS PLC, Ecolab, Inc., TOMI Environmental Solutions, Inc., JCE Biotechnology SAS, Fedegari Autoclavi S.p.A., Zhejiang TAILIN Bioengineering Co., Ltd., Howorth Air Technology Limited, Solidfog Technologies SPRL, ClorDiSys Solutions, Inc., and Amira Srl.
The expanding pharmaceutical and biotechnology sectors propel the market for bio-decontamination, an increase in hospital-acquired illnesses, and a rise in the need for affordable and transportable solutions. Bio-decontamination products are frequently used by pharmaceutical and biotechnology firms, primarily for producing parenteral drugs. Thus, the necessity for production facilities outfitted with cutting-edge equipment, including UV-C disinfection robots and a decontaminated atmosphere, is crucial given the increased R&D spending and rising demand for novel pharmaceuticals and therapies. There will be a greater need for bio-decontamination goods to conduct effective research and manufacturing.
Another aspect fueling the market's revenue growth is improved bio-decontamination service outsourcing. Pharmaceutical production facilities and business laboratories must employ strict contamination control measures. Given that contamination control must be largely a preventative strategy, cleaning and disinfection procedures must be carried out with great care. Decontamination can be outsourced as a viable solution when there has been some intervention in the region (new installation, maintenance, etc.) or when it is only being done annually or biannually as a precautionary measure. This development in outsourcing services is anticipated to promote market revenue growth.
Chronic disease is one of the most common and expensive medical disorders in the US. Approximately 45% of all Americans, or 133 million people, have at least one chronic illness, which is steadily rising. Chronic conditions can lead to hospitalization, long-term impairment, a decline in quality of life, and even death. These conditions include stroke,cancer, diabetes, respiratory illnesses, hypertension, heart conditions, arthritis, obesity, and oral illnesses. The main cause of death and disability in the US is persistent conditions.
In Canada's Northwest Territories, chronic diseases are to blame for seven out of ten causes of death, with cancer or heart disease accounting for almost half of all fatalities. Furthermore, as the population ages, it is predicted that the burden of chronic disease will rise. Asthma, diabetes, chronic obstructive pulmonary disease,hypertension, and mental disorders are all common and rising in the Northwest Territories. There is expected to be an increase in the requirement for bio decontamination in medical facilities due to the increased incidence of chronic diseases, which also increases the frequency of admissions,hospital visits,and surgeries.
The US market dominated the North America Bio Decontamination Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $99,141.7 Thousands by 2030. The Canada market is showcasing a CAGR of 8.5% during (2023-2030). Additionally, The Mexico market would register a CAGR of 7.6% during (2023-2030).
Based on Agent Type, the market is segmented into Hydrogen Peroxide, Chlorine Dioxide, Paracetic Oxide, and Nitrogen Dioxide. Based on Product & Service, the market is segmented into Equipment, Services, and Consumables. Based on Type, the market is segmented into Chamber Decontamination, and Room Decontamination. Based on End-user, the market is segmented into Pharma & Medical Device Companies, Life Science & Biotechnology Research Organizations, and Hospitals & Healthcare Facilities. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include STERIS PLC, Ecolab, Inc., TOMI Environmental Solutions, Inc., JCE Biotechnology SAS, Fedegari Autoclavi S.p.A., Zhejiang TAILIN Bioengineering Co., Ltd., Howorth Air Technology Limited, Solidfog Technologies SPRL, ClorDiSys Solutions, Inc., and Amira Srl.
Scope of the Study
By Agent Type
- Hydrogen Peroxide
- Chlorine Dioxide
- Paracetic Oxide
- Nitrogen Dioxide
By Product & Service
- Equipment
- Services
- Consumables
By Type
- Chamber Decontamination
- Room Decontamination
By End-user
- Pharma & Medical Device Companies
- Life Science & Biotechnology Research Organizations
- Hospitals & Healthcare Facilities
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- STERIS PLC
- Ecolab, Inc.
- TOMI Environmental Solutions, Inc.
- JCE Biotechnology SAS
- Fedegari Autoclavi S.p.A.
- Zhejiang TAILIN Bioengineering Co., Ltd.
- Howorth Air Technology Limited
- Solidfog Technologies SPRL
- ClorDiSys Solutions, Inc.
- Amira Srl
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market At a Glance
Chapter 3. Market Overview
Chapter 4. North America Bio Decontamination Market by Agent Type
Chapter 5. North America Bio Decontamination Market by Product & Service
Chapter 6. North America Bio Decontamination Market by Type
Chapter 7. North America Bio Decontamination Market by End User
Chapter 8. North America Bio Decontamination Market by Country
Chapter 9. Company Profiles
Companies Mentioned
- STERIS PLC
- Ecolab, Inc.
- TOMI Environmental Solutions, Inc.
- JCE Biotechnology SAS
- Fedegari Autoclavi S.p.A.
- Zhejiang TAILIN Bioengineering Co., Ltd.
- Howorth Air Technology Limited
- Solidfog Technologies SPRL
- ClorDiSys Solutions, Inc.
- Amira Srl
Methodology
LOADING...
